PCL Inc
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PC… Read more
PCL Inc (241820) - Net Assets
Latest net assets as of December 2024: ₩7.12 Billion KRW
Based on the latest financial reports, PCL Inc (241820) has net assets worth ₩7.12 Billion KRW as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩21.58 Billion) and total liabilities (₩14.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩7.12 Billion |
| % of Total Assets | 32.98% |
| Annual Growth Rate | 4.02% |
| 5-Year Change | -80.64% |
| 10-Year Change | N/A |
| Growth Volatility | 177.21 |
PCL Inc - Net Assets Trend (2015–2024)
This chart illustrates how PCL Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PCL Inc (2015–2024)
The table below shows the annual net assets of PCL Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩7.12 Billion | -81.08% |
| 2023-12-31 | ₩37.61 Billion | +19.18% |
| 2022-12-31 | ₩31.56 Billion | +116.91% |
| 2021-12-31 | ₩14.55 Billion | -60.41% |
| 2020-12-31 | ₩36.75 Billion | +531.23% |
| 2019-12-31 | ₩5.82 Billion | -40.24% |
| 2018-12-31 | ₩9.74 Billion | -36.89% |
| 2017-12-31 | ₩15.44 Billion | +106.88% |
| 2016-12-31 | ₩7.46 Billion | +49.57% |
| 2015-12-31 | ₩4.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to PCL Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10878614564000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩119.30 Billion | 1676.45% |
| Total Equity | ₩7.12 Billion | 100.00% |
PCL Inc Competitors by Market Cap
The table below lists competitors of PCL Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INNOVATEC S.P.A.
F:5JT
|
$8.68 Million |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
$8.68 Million |
|
Educational Development Corporation
NASDAQ:EDUC
|
$8.68 Million |
|
Promateris SA
RO:PPL
|
$8.68 Million |
|
Morien Resources Corp
PINK:APMCF
|
$8.67 Million |
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
$8.67 Million |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
$8.67 Million |
|
Madison Metals Inc.
OTCQB:MMTLF
|
$8.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PCL Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 35,491,103,700 to 7,116,364,800, a change of -28,374,738,900 (-79.9%).
- Net loss of 52,338,959,350 reduced equity.
- New share issuances of 24,004,997,060 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-52.34 Billion | -735.47% |
| Share Issuances | ₩24.00 Billion | +337.32% |
| Other Changes | ₩-40.78 Million | -0.57% |
| Total Change | ₩- | -79.95% |
Book Value vs Market Value Analysis
This analysis compares PCL Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.30x to 2.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1011.56 | ₩302.00 | x |
| 2017-12-31 | ₩1730.33 | ₩302.00 | x |
| 2018-12-31 | ₩1089.63 | ₩302.00 | x |
| 2019-12-31 | ₩611.00 | ₩302.00 | x |
| 2020-12-31 | ₩3646.17 | ₩302.00 | x |
| 2021-12-31 | ₩417.60 | ₩302.00 | x |
| 2022-12-31 | ₩785.52 | ₩302.00 | x |
| 2023-12-31 | ₩688.76 | ₩302.00 | x |
| 2024-12-31 | ₩120.27 | ₩302.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PCL Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -735.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4199.97%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 3.03x
- Recent ROE (-735.47%) is below the historical average (-125.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -37.37% | -767.08% | 0.04x | 1.32x | ₩-2.36 Billion |
| 2016 | -31.37% | -397.55% | 0.07x | 1.19x | ₩-3.09 Billion |
| 2017 | -25.07% | -764.45% | 0.03x | 1.03x | ₩-5.41 Billion |
| 2018 | -59.24% | -4489.80% | 0.01x | 1.09x | ₩-6.75 Billion |
| 2019 | -136.83% | -22244.14% | 0.00x | 2.70x | ₩-8.55 Billion |
| 2020 | 53.09% | 36.34% | 1.23x | 1.19x | ₩15.83 Billion |
| 2021 | -217.67% | -68.63% | 0.58x | 5.45x | ₩-33.12 Billion |
| 2022 | -12.73% | -10.79% | 0.42x | 2.79x | ₩-7.17 Billion |
| 2023 | -57.25% | -241.03% | 0.14x | 1.75x | ₩-23.87 Billion |
| 2024 | -735.47% | -4199.97% | 0.06x | 3.03x | ₩-53.05 Billion |
Industry Comparison
This section compares PCL Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $99,780,344,800
- Average return on equity (ROE) among peers: 4.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PCL Inc (241820) | ₩7.12 Billion | -37.37% | 2.03x | $8.68 Million |
| Shinhung (004080) | $91.90 Billion | 13.53% | 0.59x | $10.78 Million |
| Osang Healthcare Co.,Ltd (036220) | $285.75 Billion | -3.98% | 0.03x | $37.29 Million |
| HansBiomed Corporation (042520) | $65.30 Billion | 6.15% | 0.41x | $246.58 Million |
| JVM Co. Ltd (054950) | $137.36 Billion | 7.60% | 0.46x | $117.14 Million |
| Huvitz Co. Ltd (065510) | $121.79 Billion | 7.15% | 0.82x | $42.98 Million |
| Vieworks Co. Ltd (100120) | $140.80 Billion | 14.75% | 0.11x | $100.60 Million |
| Corentec Co Ltd (104540) | $54.32 Billion | -13.58% | 0.85x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $28.16 Million |
| Hana Must SPAC 2 (208370) | $63.80 Billion | 4.94% | 0.10x | $47.77 Million |